Achaogen
  • Company Overview Our Culture Management Team Board of Directors Scientific Advisory Board
  • Overview MDR Gram-Negative Infections Our Science
  • Pipeline Overview Plazomicin C-Scape Monoclonal Antibody Program Additional Gram-Negative Programs Scientific Publications
  • Investor Overview Press Releases Events & Presentations Corporate Governance Financials & Filings Stock Information Contact Us
  • Overview Values Benefits Positions Available Postdoctoral Program Fellowship
  • Contact Information Medical Information
Achaogen
  • About Us/
    • Company Overview
    • Our Culture
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Focus/
    • Overview
    • MDR Gram-Negative Infections
    • Our Science
  • Pipeline/
    • Pipeline Overview
    • Plazomicin
    • C-Scape
    • Monoclonal Antibody Program
    • Additional Gram-Negative Programs
    • Scientific Publications
  • Investors/
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Contact Us
  • Careers/
    • Overview
    • Values
    • Benefits
    • Positions Available
    • Postdoctoral Program
    • Fellowship
  • Contact Us/
    • Contact Information
    • Medical Information
  • /
Proteus v3 (low res).jpg
Achaogen

Media

Achaogen
  • About Us/
    • Company Overview
    • Our Culture
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Focus/
    • Overview
    • MDR Gram-Negative Infections
    • Our Science
  • Pipeline/
    • Pipeline Overview
    • Plazomicin
    • C-Scape
    • Monoclonal Antibody Program
    • Additional Gram-Negative Programs
    • Scientific Publications
  • Investors/
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Contact Us
  • Careers/
    • Overview
    • Values
    • Benefits
    • Positions Available
    • Postdoctoral Program
    • Fellowship
  • Contact Us/
    • Contact Information
    • Medical Information
  • /
June 29, 2009

Achaogen Named One Of 2009 "Fierce 15" Biotechnology Companies

June 29, 2009/ Jen Cheung

"Achaogen has set its sights on developing a new generation of antibacterials. Its lead program has just finished a Phase I safety trial with positive results, government grants have poured in and a new venture round will keep the company well financed."

FierceBiotech

Read article @ FierceBiotech.com

June 29, 2009/ Jen Cheung/
Achaogen in the News
2009

Jen Cheung

  • FierceBiotech Names Achaogen as One ...
  • Achaogen Data Show Rapid Rise in ...

© Achaogen, Inc. 2004-present. All rights reserved.     Privacy Policy | Terms of Use